International expert opinion on the management of infection caused by azole-resistant Aspergillus fumigatus

Drug Resistance Updates

Volumn 21-22, Issue , 2015, Pages 30-40

  Verweij, Paul E ^a   Ananda Rajah, Michelle ^b   Andes, David ^c   Arendrup, Maiken C ^d   Brüggemann, Roger J ^a   Chowdhary, Anuradha ^e   Cornely, Oliver A ^f   Denning, David W ^g   Groll, Andreas H ^h   Izumikawa, Koichi ⁱ   Kullberg, Bart Jan ^a   Lagrou, Katrien ^j   Maertens, Johan ^j   Meis, Jacques F ^a,k   Newton, Pippa ^g   Page, Iain ^g   Seyedmousavi, Seyedmojtaba ^a   Sheppard, Donald C ^l   Viscoli, Claudio ^m   Warris, Adilia ⁿ   Donnelly, J Peter ^a   more..

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^b General Medicine and Infectious Diseases Units Alfred Health ^*  (Australia)

^c UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

^d STATENS SERUM INSTITUT   (Denmark)

^e UNIVERSITY OF DELHI   (India)

^f Cologne Excellence Cluster on Cellular Stress Responses in Aging Associated Diseases   (Germany)

^g MANCHESTER UNIVERSITY NHS FOUNDATION TRUST   (United Kingdom)

^h UNIVERSITY HOSPITAL MÜNSTER   (Germany)

ⁱ NAGASAKI UNIVERSITY GRADUATE SCHOOL OF BIOMEDICAL SCIENCES   (Japan)

^j UNIVERSITY OF LEUVEN   (Belgium)

^k CANISIUS WILHELMINA HOSPITAL   (Netherlands)

^l MCGILL UNIVERSITY   (Canada)

^m UNIVERSITY OF GENOA   (Italy)

ⁿ UNIVERSITY OF ABERDEEN   (United Kingdom)

more..

Author keywords

Aspergillus fumigatus; Azole resistance; Chronic aspergillosis; Invasive aspergillosis; Voriconazole

Indexed keywords

AMPHOTERICIN B; AMPHOTERICIN B CHOLESTEROL SULFATE; AMPHOTERICIN B LIPID COMPLEX; ANIDULAFUNGIN; CASPOFUNGIN; ECHINOCANDIN; FLUCYTOSINE; ISAVUCONAZOLE; ITRACONAZOLE; MICAFUNGIN; POSACONAZOLE; VORICONAZOLE; ANTIFUNGAL AGENT; PYRROLE DERIVATIVE;

ANTIFUNGAL RESISTANCE; ANTIFUNGAL SUSCEPTIBILITY; ARTICLE; ASPERGILLOSIS; ASPERGILLUS FUMIGATUS; CENTRAL NERVOUS SYSTEM ASPERGILLOSIS; HUMAN; INVASIVE ASPERGILLOSIS; LUNG ASPERGILLOSIS; MICROBIOLOGICAL EXAMINATION; NONHUMAN; PRIORITY JOURNAL; TREATMENT OUTCOME; COMBINATION DRUG THERAPY; DRUG DESIGN; DRUG EFFECTS; ISOLATION AND PURIFICATION; MICROBIAL SENSITIVITY TEST; MICROBIOLOGY; MULTIDRUG RESISTANCE; PULMONARY ASPERGILLOSIS;

ANTIFUNGAL AGENTS; ASPERGILLOSIS; ASPERGILLUS FUMIGATUS; AZOLES; DRUG DESIGN; DRUG RESISTANCE, FUNGAL; DRUG RESISTANCE, MULTIPLE, FUNGAL; DRUG THERAPY, COMBINATION; HUMANS; MICROBIAL SENSITIVITY TESTS; PULMONARY ASPERGILLOSIS;

EID: 84941317313     PISSN: 13687646     EISSN: 15322084     Source Type: Journal    
DOI: 10.1016/j.drup.2015.08.001     Document Type: Article

References (104)

1. R. Agarwal, G. Vishwanath, A.N. Aggarwal, M. Garg, D. Gupta, and A. Chakrabarti Itraconazole in chronic cavitary pulmonary aspergillosis: a randomised controlled trial and systematic review of literature Mycoses 56 2013 559 570
2. S. Ahmad, Z. Khan, F. Hagen, and J.F. Meis Occurrence of triazole-resistant Aspergillus fumigatus with TR34/L98H mutations in outdoor and hospital environment in Kuwait Environ. Res. 133 2014 20 26
3. K. Al-Shair, G.T. Atherton, C. Harris, L. Ratcliffe, P.J. Newton, and D.W. Denning Long-term antifungal treatment improves health status in patients with chronic pulmonary aspergillosis: a longitudinal analysis Clin. Infect. Dis. 57 2013 828 835
4. M.C. Arendrup, M. Cuenca-Estrella, C. Lass-Flörl, and W.W. Hope Breakpoints for antifungal agents: an update from EUCAST focussing on echinocandins against Candida spp. and triazoles against Aspergillus spp. Drug Resist. Updates 16 2013 81 95
5. J. Arroyo, G. Medoff, and G.S. Kobayashi Therapy of murine aspergillosis with amphotericin B in combination with rifampin of 5-fluorocytosine Antimicrob. Agents Chemother. 11 1977 21 25
6. K.M. Astvad, R.H. Jensen, T.M. Hassan, E.G. Mathiasen, G.M. Thomsen, U.G. Pedersen, M. Christensen, O. Hilberg, and M.C. Arendrup First detection of TR46/Y121F/T289A and TR34/L98H alterations in Aspergillus fumigatus isolates from azole-naive patients in Denmark despite negative findings in the environment Antimicrob. Agents Chemother. 58 2014 5096 5101
7. H. Badali, A. Vaezi, I. Haghani, S.A. Yazdanparast, M.T. Hedayati, B. Mousavi, S. Ansari, F. Hagen, J.F. Meis, and A. Chowdhary Environmental study of azole-resistant Aspergillus fumigatus with TR34/L98H mutations in the cyp51A gene in Iran Mycoses 56 2013 659 663
8. J.W. Baddley, D.R. Andes, K.A. Marr, D.P. Kontoyiannis, B.D. Alexander, C.A. Kauffman, R.A. Oster, E.J. Anaissie, T.J. Walsh, M.G. Schuster, J.R. Wingard, T.F. Patterson, J.I. Ito, O.D. Williams, T. Chiller, and P.G. Pappas Factors associated with mortality in transplant patients with invasive aspergillosis Clin. Infect. Dis. 50 2010 1559 1567
9. O. Bader, J. Tünnermann, A. Dudakova, M. Tangwattanachuleeporn, M. Weig, and U. Groß Environmental azole resistant Aspergillus fumigatus in Germany Antimicrob. Agents Chemother. 59 2015 4356 4359
10. D. Bitar, O. Lortholary, Y. Le Strat, J. Nicolau, B. Coignard, P. Tattevin, D. Che, and F. Dromer Population-based analysis of invasive fungal infections France, 2001-2010 Emerg. Infect. Dis. 20 2014 1149 1155
11. E.R. Block, and J.E. Bennett Pharmacological studies with 5-fluorocytosine Antimicrob. Agents Chemother. 1 1972 476 482
12. G.D. Brown, D.W. Denning, N.A. Gow, S.M. Levitz, M.G. Netea, and T.C. White Hidden killers: human fungal infections Sci. Transl. Med. 4 2012 165rv13
13. P.A. Burch, J.E. Karp, W.G. Merz, J.E. Kuhlman, and E.K. Fishman Favorable outcome of invasive aspergillosis in patients with acute leukemia J. Clin. Oncol. 5 1987 1985 1993
14. S.M. Camps, J.W. van der Linden, Y. Li, E.J. Kuijper, J.T. van Dissel, P.E. Verweij, and W.J. Melchers Rapid induction of multiple resistance mechanisms in Aspergillus fumigatus during azole therapy: a case study and review of the literature Antimicrob. Agents Chemother. 56 2012 10 16
15. L. Chishimba, P. Langridge, G. Powell, R.M. Niven, and D.W. Denning Efficacy and safety of nebulised amphotericin B (NAB) in severe asthma with fungal sensitisation (SAFS) and allergic bronchopulmonary aspergillosis (ABPA) J. Asthma 23 2014 1 7
16. G.L. Chong, W.W. van de Sande, G.J. Dingemans, G.R. Gaajetaan, A.G. Vonk, M.P. Hayette, D.W. van Tegelen, G.F. Simons, and B.J. Rijnders Validation of a new Aspergillus real-time PCR assay for direct detection of Aspergillus and azole resistance of Aspergillus fumigatus on bronchoalveolar lavage fluid J. Clin. Microbiol. 53 2015 868 874
17. A. Chowdhary, S. Kathuria, H.S. Randhawa, S.N. Gaur, C.H. Klaassen, and J.F. Meis Isolation of multiple-triazole-resistant Aspergillus fumigatus strains carrying the TR/L98H mutations in the cyp51A gene in India J. Antimicrob. Chemother. 67 2012 362 366
18. A. Chowdhary, S. Kathuria, J. Xu, and J.F. Meis Emergence of azole-resistant Aspergillus fumigatus strains due to agricultural azole use creates an increasing threat to human health PLOS Pathog. 9 2013 e1003633
19. A. Chowdhary, C. Sharma, S. Kathuria, F. Hagen, and J.F. Meis Azole-resistant Aspergillus fumigatus with the environmental TR46/Y121F/T289A mutation in India J. Antimicrob. Chemother. 69 2014 555 557
20. A. Chowdhary, C. Sharma, M. van den Boom, J.B. Yntema, F. Hagen, P.E. Verweij, and J.F. Meis Multi-azole-resistant Aspergillus fumigatus in the environment in Tanzania J. Antimicrob. Chemother. 69 2014 2979 2983
21. A. Chowdhary, C. Sharma, S. Kathuria, F. Hagen, and J.F. Meis Prevalence and mechanism of triazole resistance in Aspergillus fumigatus in a referral chest hospital in Delhi, India and an update of the situation in Asia Front. Microbiol. 6 2015 428
22. Clinical Laboratory Standards Institute Reference Method for Broth Dilution Antifungal Susceptibility Testing of Filamentous Fungi; Approved Standard. Document M38-A2 2nd ed. 2008 CLSI Wayne, PA
23. J.M. Coleman, G.G. Hogg, J.V. Rosenfeld, and K.D. Waters Invasive central nervous system aspergillosis: cure with liposomal amphotericin B, itraconazole, and radical surgery - case report and review of the literature Neurosurgery 36 1995 858 863
24. O.A. Cornely, J.J. Vehreschild, M.J. Vehreschild, G. Würthwein, D. Arenz, S. Schwartz, C.P. Heussel, G. Silling, M. Mahne, J. Franklin, U. Harnischmacher, A. Wilkens, F. Farowski, M. Karthaus, T. Lehrnbecher, A.J. Ullmann, M. Hallek, and A.H. Groll Phase II dose escalation study of caspofungin for invasive aspergillosis Antimicrob. Agents Chemother. 55 2011 5798 5803
25. D.W. Denning Echinocandin antifungal drugs Lancet 362 2003 1142 1151
26. D.W. Denning, and M.J. Bromley Infectious disease. How to bolster the antifungal pipeline Science 347 2015 1414 1416
27. D.W. Denning, and D.A. Stevens Antifungal and surgical treatment of invasive aspergillosis: review of 2,121 published cases Rev. Infect. Dis. 12 1990 1147 1201
28. D.W. Denning, S. Park, C. Lass-Florl, M.G. Fraczek, M. Kirwan, R. Gore, J. Smith, A. Bueid, C.B. Moore, P. Bowyer, and D.S. Perlin High-frequency triazole resistance found in nonculturable Aspergillus fumigatus from lungs of patients with chronic fungal disease Clin. Infect. Dis. 52 2011 1123 1129
29. D.W. Denning, A. Pleuvry, and D.C. Cole Global burden of chronic pulmonary aspergillosis as a sequel to tuberculosis Bull. WHO 89 2011 864 872
30. D.W. Denning, A. Pleuvry, and D.C. Cole Global burden of allergic bronchopulmonary aspergillosis with asthma and its complication chronic pulmonary aspergillosis in adults Med. Mycol. 51 2013 361 370
31. P. Escribano, S. Recio, T. Peláez, M. González-Rivera, E. Bouza, and J. Guinea In vitro acquisition of secondary azole resistance in Aspergillus fumigatus isolates after prolonged exposure to itraconazole: presence of heteroresistant populations Antimicrob. Agents Chemother. 56 2012 174 178
32. A. Espinel-Ingroff, A. Chowdhary, G.M. Gonzalez, C. Lass-Flörl, E. Martin-Mazuelos, J.F. Meis, T. Peláez, M.A. Pfaller, and J. Turnidge Multicenter study of isavuconazole MIC distributions and epidemiological cutoff values for Aspergillus spp. for the CLSI M38-A2 broth microdilution method Antimicrob. Agents Chemother. 57 2013 3823 3828
33. S. Farid, S. Mohamed, M. Devbhandari, M. Kneale, M. Richardson, S.Y. Soon, M.T. Jones, P. Krysiak, R. Shah, D.W. Denning, and K. Rammohan Results of surgery for chronic pulmonary aspergillosis, optimal antifungal therapy and proposed high risk factors for recurrence - a National Centre's experience J. Cardiothorac. Surg. 8 2013 180
34. T. Felton, P.F. Troke, and W.W. Hope Tissue penetration of antifungal agents Clin. Microbiol. Rev. 27 2014 68 88
35. M.G. Fraczek, M.B. Kirwan, C.B. Moore, J. Morris, D.W. Denning, and M.D. Richardson Volume dependency for culture of fungi from respiratory secretions and increased sensitivity of Aspergillus quantitative PCR Mycoses 57 2014 69 78
36. L. Gregson, J. Goodwin, A. Johnson, L. McEntee, C.B. Moore, M. Richardson, W.W. Hope, and S.J. Howard In vitro susceptibility of Aspergillus fumigatus to isavuconazole: correlation with itraconazole, voriconazole, and posaconazole Antimicrob. Agents Chemother. 57 2013 5778 5780
37. A.H. Groll, N. Giri, V. Petraitis, R. Petraitiene, M. Candelario, J.S. Bacher, S.C. Piscitelli, and T.J. Walsh Comparative efficacy and distribution of lipid formulations of amphotericin B in experimental Candida albicans infection of the central nervous system J. Infect. Dis. 182 2000 274 282
38. R. Herbrecht, D.W. Denning, T.F. Patterson, J.E. Bennett, R.E. Greene, J.W. Oestmann, W.V. Kern, K.A. Marr, P. Ribaud, O. Lortholary, R. Sylvester, R.H. Rubin, J.R. Wingard, P. Stark, C. Durand, D. Caillot, E. Thiel, P.H. Chandrasekar, M.R. Hodges, H.T. Schlamm, P.F. Troke, B. de Pauw Invasive Fungal Infections Group of the European Organisation for Research and Treatment of Cancer and the Global Aspergillus Study Group Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis N. Engl. J. Med. 347 2002 408 415
39. R. Herbrecht, J. Maertens, L. Baila, M. Aoun, W. Heinz, R. Martino, S. Schwartz, A.J. Ullmann, L. Meert, M. Paesmans, O. Marchetti, H. Akan, L. Ameye, M. Shivaprakash, and C. Viscoli Caspofungin first-line therapy for invasive aspergillosis in allogeneic hematopoietic stem cell transplant patients: an European Organisation for Research and Treatment of Cancer study Bone Marrow Transplant 45 2010 1227 1233
40. R. Herbrecht, T.F. Patterson, M.A. Slavin, O. Marchetti, J. Maertens, E.M. Johnson, H.T. Schlamm, J.P. Donnelly, and P.G. Pappas Application of the 2008 definitions for invasive fungal diseases to the trial comparing voriconazole versus amphotericin B for therapy of invasive aspergillosis: a collaborative study of the Mycoses Study Group (MSG 05) and the European Organization for Research and Treatment of Cancer Infectious Diseases Group Clin. Infect. Dis. 60 2015 713 720
41. S.J. Howard, D. Cerar, M.J. Anderson, A. Albarrag, M.C. Fisher, A.C. Pasqualotto, M. Laverdiere, M.C. Arendrup, D.S. Perlin, and D.W. Denning Frequency and evolution of azole resistance in Aspergillus fumigatus associated with treatment failure Emerg. Infect. Dis. 15 2009 1068 1076
42. S.J. Howard, A.C. Pasqualotto, M.J. Anderson, H. Leatherbarrow, A.M. Albarrag, E. Harrison, L. Gregson, P. Bowyer, and D.W. Denning Major variations in Aspergillus fumigatus arising within aspergillomas in chronic pulmonary aspergillosis Mycoses 56 2013 434 441
43. S.J. Howard, C. Lass-Flörl, M. Cuenca-Estrella, A. Gomez-Lopez, and M.C. Arendrup Determination of isavuconazole susceptibility of Aspergillus and Candida species by the EUCAST method Antimicrob. Agents Chemother. 57 2013 5426 5431
44. K. Izumikawa, Y. Ohtsu, M. Kawabata, H. Takaya, A. Miyamoto, S. Sakamoto, K. Kishi, E. Tsuboi, S. Homma, and K. Yoshimura Clinical efficacy of micafungin for chronic pulmonary aspergillosis Med. Mycol. 45 2007 273 278
45. J. Jans, R.J. Brüggemann, V. Christmann, P.E. Verweij, and A. Warris Favorable outcome of neonatal cerebrospinal fluid shunt-associated Candida meningitis with caspofungin Antimicrob. Agents Chemother. 57 2013 2391 2393
46. A.R. Jeans, S.J. Howard, Z. Al-Nakeeb, J. Goodwin, L. Gregson, P.A. Warn, and W.W. Hope Combination of voriconazole and anidulafungin for treatment of triazole-resistant Aspergillus fumigatus in an in vitro model of invasive pulmonary aspergillosis Antimicrob. Agents Chemother. 56 2012 5180 5185
47. G.J. Keir, B. Garfield, D.M. Hansell, M.R. Loebinger, R. Wilson, E.A. Renzoni, A.U. Wells, and T.M. Maher Cyclical caspofungin for chronic pulmonary aspergillosis in sarcoidosis Thorax 69 2014 287 288
48. S. Kethireddy, and D. Andes CNS pharmacokinetics of antifungal agents Expert Opin. Drug Metab. Toxicol. 3 2007 573 581
49. S.E. Kidd, E. Goeman, J.F. Meis, M.A. Slavin, and P.E. Verweij Multi-triazole-resistant Aspergillus fumigatus infections in Australia Mycoses 58 2015 350 355
50. S. Kohno, T. Masaoka, H. Yamaguchi, T. Mori, A. Urabe, A. Ito, Y. Niki, and H. Ikemoto A multicenter, open-label clinical study of micafungin (FK463) in the treatment of deep-seated mycosis in Japan Scand. J. Infect. Dis. 36 2004 372 379
51. S. Kohno, K. Izumikawa, K. Ogawa, A. Kurashima, N. Okimoto, R. Amitani, H. Kakeya, Y. Niki, Y. Miyazaki Japan Chronic Pulmonary Aspergillosis Study Group (JCPASG) Intravenous micafungin versus voriconazole for chronic pulmonary aspergillosis: a multicentre trial in Japan J. Infect. 61 2010 410 418
52. S. Kohno, K. Izumikawa, H. Kakeya, Y. Miyazaki, K. Ogawa, R. Amitani, Y. Niki, and A. Kurashima Clinical efficacy and safety of micafungin in Japanese patients with chronic pulmonary aspergillosis: a prospective observational study Med. Mycol. 49 2011 688 693
53. S. Kohno, K. Izumikawa, M. Yoshida, Y. Takesue, S. Oka, K. Kamei, Y. Miyazaki, T. Yoshinari, N.A. Kartsonis, and Y. Niki A double-blind comparative study of the safety and efficacy of caspofungin versus micafungin in the treatment of candidiasis and aspergillosis Eur. J. Clin. Microbiol. Infect. Dis. 32 2013 387 397
54. T.K. Kourkoumpetis, A. Desalermos, M. Muhammed, and E. Mylonakis Central nervous system aspergillosis: a series of 14 cases from a general hospital and review of 123 cases from the literature Medicine (Baltimore) 91 2012 328 336
55. R.A. Lavergne, F. Morio, L. Favennec, S. Dominique, J.F. Meis, G. Gargala, P.E. Verweij, and P. Le Pape First description of azole-resistant Aspergillus fumigatus due to TR46/Y121F/T289A mutation in France Antimicrob. Agents Chemother. 59 2015 4331 4335
56. J.W. Lee, M.A. Amantea, P.A. Francis, E.E. Navarro, J. Bacher, P.A. Pizzo, and T.J. Walsh Pharmacokinetics and safety of a unilamellar liposomal formulation of amphotericin B (AmBisome) in rabbits Antimicrob. Agents Chemother. 38 1994 713 718
57. A.J. Lepak, K. Marchillo, J. Vanhecker, and D.R. Andes Posaconazole pharmacodynamic target determination against wild-type and Cyp51 mutant isolates of Aspergillus fumigatus in an in vivo model of invasive pulmonary aspergillosis Antimicrob. Agents Chemother. 57 2013 579 585
58. A.J. Lepak, K. Marchillo, J. Vanhecker, and D.R. Andes Isavuconazole (BAL4815) pharmacodynamic target determination in an in vivo murine model of invasive pulmonary aspergillosis against wild-type and cyp51 mutant isolates of Aspergillus fumigatus Antimicrob. Agents Chemother. 57 2013 6284 6289
59. S.R. Lockhart, J.P. Frade, K.A. Etienne, M.A. Pfaller, D.J. Diekema, and S.A. Balajee Azole resistance in Aspergillus fumigatus isolates from the ARTEMIS global surveillance study is primarily due to the TR/L98H mutation in the cyp51A gene Antimicrob. Agents Chemother. 55 2011 4465 4468
60. O. Lortholary, J.P. Gangneux, K. Sitbon, B. Lebeau, F. de Monbrison, Y. Le Strat, B. Coignard, F. Dromer, S. Bretagne French Mycosis Study Group Epidemiological trends in invasive aspergillosis in France: the SAIF network (2005-2007) Clin. Microbiol. Infect. 17 2011 1882 1889
61. J. Maertens, I. Raad, G. Petrikkos, M. Boogaerts, D. Selleslag, F.B. Petersen, C. Sable, N. Kartsonis, A. Ngai, A. Taylor, T. Patterson, D.W. Denning, and T.J. Walsh A multicenter, open, noncomparative study to estimate the safety, tolerability and efficacy of caspofungin (MK-0991) in the treatment of invasive aspergillus infections in adults who are refractory to or intolerant of amphotericin B, lipid formulations of amphotericin B or azoles Clin. Infect. Dis. 39 2004 1563 1571
62. J. Maertens, O. Marchetti, R. Herbrecht, O.A. Cornely, U. Flückiger, P. Frêre, B. Gachot, W.J. Heinz, C. Lass-Flörl, P. Ribaud, A. Thiebaut, C. Cordonnier, and Third European Conference on Infections in Leukemia European guidelines for antifungal management in leukemia and hematopoietic stem cell transplant recipients: summary of the ECIL3 2009 update Bone Marrow Transplant 46 2011 709 718
63. K.A. Marr, H.T. Schlamm, R. Herbrecht, S.T. Rottinghaus, E.J. Bow, O.A. Cornely, W.J. Heinz, S. Jagannatha, L.P. Koh, D.P. Kontoyiannis, D.G. Lee, M. Nucci, P.G. Pappas, M.A. Slavin, F. Queiroz-Telles, D. Selleslag, T.J. Walsh, J.R. Wingard, and J.A. Maertens Combination antifungal therapy for invasive aspergillosis: a randomized trial Ann. Intern. Med. 162 2015 81 89
64. K. Nakamoto, N. Takayanagi, T. Kanauchi, T. Ishiguro, T. Yanagisawa, and Y. Sugita Prognostic factors in 194 patients with chronic necrotizing pulmonary aspergillosis Intern. Med. 52 2013 727 734
65. D. Neofytos, D. Horn, E. Anaissie, W. Steinbach, A. Olyaei, J. Fishman, M. Pfaller, C. Chang, K. Webster, and K. Marr Epidemiology and outcome of invasive fungal infection in adult hematopoietic stem cell transplant recipients: analysis of Multicenter Prospective Antifungal Therapy (PATH) Alliance registry Clin. Infect. Dis. 48 2009 265 273
66. P.N. Newton, C. Harris, and D.W. Denning The clinical response to a short-term course of intravenous liposomal amphotericin B therapy in patients with chronic pulmonary aspergillosis Mycoses 56 Suppl. 3 2013 164 165
67. Y. Nivoix, M. Velten, V. Letscher-Bru, A. Moghaddam, S. Natarajan-Amé, C. Fohrer, B. Lioure, K. Bilger, P. Lutun, L. Marcellin, A. Launoy, G. Freys, J.P. Bergerat, and R. Herbrecht Factors associated with overall and attributable mortality in invasive aspergillosis Clin. Infect. Dis. 47 2008 1176 1184
68. H. Ohba, S. Miwa, M. Shirai, M. Kanai, T. Eifuku, T. Suda, H. Hayakawa, and K. Chida Clinical characteristics and prognosis of chronic pulmonary aspergillosis Respir. Med. 106 2012 724 729
69. G.E. Özmerdiven, S. Ak, B. Ener, H. Aʇca, B.D. Cilo, B. Tunca, and H. Akalin First determination of azole resistance in Aspergillus fumigatus strains carrying the TR34/L98H mutations in Turkey J. Infect. Chemother. 21 2015 581 586
70. L. Pagano, M. Caira, A. Candoni, M. Offidani, B. Martino, G. Specchia, D. Pastore, M. Stanzani, C. Cattaneo, R. Fanci, C. Caramatti, F. Rossini, M. Luppi, L. Potenza, F. Ferrara, M.E. Mitra, R.M. Fadda, R. Invernizzi, T. Aloisi, M. Picardi, A. Bonini, A. Vacca, A. Chierichini, L. Melillo, C. de Waure, L. Fianchi, M. Riva, G. Leone, F. Aversa, and A. Nosari Invasive aspergillosis in patients with acute myeloid leukemia: a SEIFEM-2008 registry study Haematologica 95 2010 644 650
71. T.F. Patterson Advances and challenges in management of invasive mycoses Lancet 366 2005 1013 1025
72. S. Perkhofer, C. Lass-Flörl, M. Hell, G. Russ, R. Krause, M. Hönigl, C. Geltner, J. Auberger, G. Gastl, M. Mitterbauer, B. Willinger, P. Knöbl, G. Resch, R. Waldner, A. Makrai, G. Hartmann, M. Girschikofsky, and R. Greil The Nationwide Austrian Aspergillus Registry: a prospective data collection on epidemiology, therapy and outcome of invasive mould infections in immunocompromised and/or immunosuppressed patients Int. J. Antimicrob. Agents 36 2010 531 536
73. M. Reinwald, B. Spiess, W.J. Heinz, C.P. Heussel, H. Bertz, O.A. Cornely, J. Hahn, T. Lehrnbecher, M. Kiehl, H.J. Laws, H.H. Wolf, R. Schwerdtfeger, B. Schultheis, A. Burchardt, M. Klein, M. Dürken, B. Claus, F. Schlegel, M. Hummel, W.K. Hofmann, and D. Buchheidt Aspergillus PCR-based investigation of fresh tissue and effusion samples in patients with suspected invasive aspergillosis enhances diagnostic capabilities J. Clin. Microbiol. 51 2013 4178 4185
74. J.L. Rodriguez-Tudela, M.C. Arendrup, S. Arikan, F. Barchisei, J. Bille, E. Chryssantou, M. Cuenca-Estrella, E. Dannaoui, D.W. Denning, J.P. Donnelly, W. Fegeler, C. Lass-Flörl, C. Moore, M. Richardson, P. Gaustad, A. Schmalreck, A. Velegraki, and P. Verweij EUCAST technical note on the method for the determination of broth dilution minimum inhibitory concentrations of antifungal agents for conidia-forming moulds Clin. Microbiol. Infect. 14 2008 982 984
75. S. Schelenz, R.A. Barnes, R.C. Barton, J.R. Cleverley, S.B. Lucas, C.C. Kibbler, D.W. Denning British Society for Medical Mycology British Society for Medical Mycology best practice recommendations for the diagnosis of serious fungal diseases Lancet Infect. Dis. 15 2015 461 474
76. S. Schwartz, M. Ruhnke, P. Ribaud, L. Corey, T. Driscoll, O.A. Cornely, U. Schuler, I. Lutsar, P. Troke, and E. Thiel Improved outcome in central nervous system aspergillosis, using voriconazole treatment Blood 106 2005 2641 2645
77. S. Schwartz, M. Ruhnke, P. Ribaud, E. Reed, P. Troke, and E. Thiel Poor efficacy of amphotericin B-based therapy in CNS aspergillosis Mycoses 50 2007 196 200
78. S. Seyedmousavi, S.J. Hashemi, E. Zibafar, J. Zoll, M.T. Hedayati, J.W. Mouton, W.J. Melchers, and P.E. Verweij Azole-resistant Aspergillus fumigatus Iran. Emerg. Infect. Dis. 19 2013 832 834
79. S. Seyedmousavi, R.J. Bruggemann, W.J. Melchers, P.E. Verweij, and J.W. Mouton Efficacy and pharmacodynamics of voriconazole combined with anidulafungin in azole-resistant invasive aspergillosis J. Antimicrob. Chemother. 68 2013 385 393
80. S. Seyedmousavi, W.J. Melchers, J.W. Mouton, and P.E. Verweij Pharmacodynamics and dose-response relationships of liposomal amphotericin B against different azole-resistant Aspergillus fumigatus isolates in a murine model of disseminated aspergillosis Antimicrob. Agents Chemother. 57 2013 1866 1871
81. S. Seyedmousavi, R.J. Brüggemann, J.F. Meis, W.J. Melchers, P.E. Verweij, and J.W. Mouton Pharmacodynamics of isavuconazole in an Aspergillus fumigatus mouse infection model Antimicrob. Agents Chemother. 59 2015 2855 2866
82. E. Snelders, H.A. van der Lee, J. Kuijpers, A.J. Rijs, J. Varga, R.A. Samson, E. Mellado, A.R. Donders, W.J. Melchers, and P.E. Verweij Emergence of azole resistance in Aspergillus fumigatus and spread of a single resistance mechanism PLOS Med. 5 2008 e219
83. E. Snelders, R.A. Huis In't Veld, A.J. Rijs, G.H. Kema, W.J. Melchers, and P.E. Verweij Possible environmental origin of resistance of Aspergillus fumigatus to medical triazoles Appl. Environ. Microbiol. 75 2009 4053 4057
84. E. Snelders, S.M. Camps, A. Karawajczyk, G. Schaftenaar, G.H. Kema, H.A. van der Lee, C.H. Klaassen, W.J. Melchers, and P.E. Verweij Triazole fungicides can induce cross-resistance to medical triazoles in Aspergillus fumigatus PLoS ONE 7 2012 e31801
85. J. Steinmann, A. Hamprecht, M.J. Vehreschild, O.A. Cornely, D. Buchheidt, B. Spiess, M. Koldehoff, J. Buer, J.F. Meis, and P.M. Rath Emergence of azole-resistant invasive aspergillosis in HSCT recipients in Germany J. Antimicrob. Chemother. 70 2015 1522 1526
86. A. Upton, K.A. Kirby, P. Carpenter, M. Boeckh, and K.A. Marr Invasive aspergillosis following hematopoietic cell transplantation: outcomes and prognostic factors associated with mortality Clin. Infect. Dis. 44 2007 531 540
87. J.W. van der Linden, R.R. Jansen, D. Bresters, C.E. Visser, S.E. Geerlings, E.J. Kuijper, W.J. Melchers, and P.E. Verweij Azole-resistant central nervous system aspergillosis Clin. Infect. Dis. 48 2009 1111 1113
88. J.W. van der Linden, E. Snelders, J.P. Arends, S.M. Daenen, W.J. Melchers, and P.E. Verweij Rapid diagnosis of azole-resistant aspergillosis by direct PCR using tissue specimens J. Clin. Microbiol. 48 2010 1478 1480
89. J.W. van der Linden, E. Snelders, G.A. Kampinga, B.J. Rijnders, E. Mattsson, Y.J. Debets-Ossenkopp, E.J. Kuijper, F.H. Van Tiel, W.J. Melchers, and P.E. Verweij Clinical implications of azole resistance in Aspergillus fumigatus The Netherlands, 2007-2009 Emerg. Infect. Dis. 17 2011 1846 1854
90. J.W. van der Linden, S.M. Camps, G.A. Kampinga, J.P. Arends, Y.J. Debets-Ossenkopp, P.J. Haas, B.J. Rijnders, E.J. Kuijper, F.H. van Tiel, J. Varga, A. Karawajczyk, J. Zoll, W.J. Melchers, and P.E. Verweij Aspergillosis due to voriconazole highly resistant Aspergillus fumigatus and recovery of genetically related resistant isolates from domiciles Clin. Infect. Dis. 57 2013 513 520
91. J.W.M. van der Linden, M.C. Arendrup, A. Warris, K. Lagrou, H. Pelloux, P.M. Hauser, E. Chryssanthou, E. Mellado, S.E. Kidd, A.M. Tortorano, E. Dannaoui, P. Gaustad, J.W. Baddley, A. Uekötter, C. Lass-Flörl, N. Klimko, C.B. Moore, D.W. Denning, A.C. Pasqualotto, C. Kibbler, S. Arikan-Akdagli, D. Andes, J. Meletiadis, L. Naumiuk, M. Nucci, W.J.G. Melchers, and P.E. Verweij Prospective multicenter international surveillance of azole resistance in Aspergillus fumigatus Emerg. Infect. Dis. 21 2015 1041 1044
92. J. van Ingen, H.A. van der Lee, T.A. Rijs, J. Zoll, T. Leenstra, W.J. Melchers, and P.E. Verweij Azole, polyene and echinocandin MIC distributions for wild-type, TR34/L98H and TR46/Y121F/T289A Aspergillus fumigatus isolates in the Netherlands J. Antimicrob. Chemother. 70 2015 178 181
93. E. Vermeulen, J. Maertens, H. Schoemans, and K. Lagrou Azole-resistant Aspergillus fumigatus due to TR46/Y121F/T289A mutation emerging in Belgium Euro Surveill. 2012 17
94. E. Vermeulen, K. Lagrou, and P.E. Verweij Azole resistance in Aspergillus fumigatus: a growing public health concern Curr. Opin. Infect. Dis. 26 2013 493 500
95. E. Vermeulen, J. Maertens, A. De Bel, E. Nulens, J. Boelens, I. Surmont, A. Mertens, A. Boel, and K. Lagrou Epidemiology of azole-resistance in aspergillus disease: a one-year prospective cohort from the Belgian Mycoses Surveillance Network Antimicrob. Agents Chemother. May 2015 pii:AAC.00233-15 (Epub ahead of print)
96. P.E. Verweij, and T. Leenstra Azole resistance in Aspergillus fumigatus NethMap 2014 Consumption of Antimicrobial Agents and Antimicrobial Resistance among Medically Important Bacteria in the Netherlands 2014 94 98
97. P.E. Verweij, D.T. Te Dorsthorst, W.H. Janssen, J.F. Meis, and J.W. Mouton In vitro activities at pH 5.0 and pH 7.0 and in vivo efficacy of flucytosine against Aspergillus fumigatus Antimicrob. Agents Chemother. 52 2008 4483 4485
98. P.E. Verweij, E. Snelders, G.H. Kema, E. Mellado, and W.J. Melchers Azole resistance in Aspergillus fumigatus: a side effect of environmental fungicide use? Lancet Infect. Dis. 9 2009 789 795
99. C. Viscoli, R. Herbrecht, H. Akan, L. Baila, A. Sonet, A. Gallamini, A. Giagounidis, O. Marchetti, R. Martino, L. Meert, M. Paesmans, L. Ameye, M. Shivaprakash, A.J. Ullmann, J. Maertens, and Infectious Disease Group of the EORTC An EORTC Phase II study of caspofungin as first-line therapy of invasive aspergillosis in haematological patients J. Antimicrob. Chemother. 64 2009 1274 1281
100. T.J. Walsh, E.J. Anaissie, D.W. Denning, R. Herbrecht, D.P. Kontoyiannis, K.A. Marr, V.A. Morrison, B.H. Segal, W.J. Steinbach, D.A. Stevens, J.A. van Burik, J.R. Wingard, and T.F. Patterson Infectious Diseases Society of America Treatment of aspergillosis: clinical practice guidelines of the Infectious Diseases Society of America Clin. Infect. Dis. 46 2008 327 360
101. P.L. White, R.B. Posso, and R.A. Barnes Analytical and clinical evaluation of the PathoNostics AsperGenius® Assay for detection of invasive aspergillosis and resistance to azole antifungal drugs during testing of serum samples J. Clin. Microbiol. 53 2015 2115 2121
102. S. Yasuda, R. Ohnishi, T. Suzuki, K. Sano, and T. Kato Short-term efficacy evaluation of chronic pulmonary aspergillosis treated with micafungin and maintenance therapy of itraconazole (article in Japanese) Nihon Kokyuki Gakkai Zasshi 47 2009 985 990
103. R.C. Young, J.E. Bennett, C.L. Vogel, P.P. Carbone, and V.T. DeVita Aspergillosis. The spectrum of the disease in 98 patients Medicine (Baltimore) 49 1970 147 173
104. Y. Zhao, C.R. Stensvold, D.S. Perlin, and M.C. Arendrup Azole resistance in Aspergillus fumigatus from bronchoalveolar lavage fluid samples of patients with chronic diseases J. Antimicrob. Chemother. 68 2013 1497 1504